- Home
- SCTX vs SLGL Comparison
SCTX vs SLGL Comparison
Compare SCTX & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCTX | SLGL |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.1M | 254.1M |
| IPO Year | 2026 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SCTX | SLGL |
|---|---|---|
| Price | $31.70 | $79.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 218.3K | 43.4K |
| Earning Date | N/A | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.31 | $21.00 |
| 52 Week High | $39.60 | $97.97 |
Technical Indicators
Market Signals| Indicator | SCTX | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | N/A |
| Support Level | $19.09 | N/A |
| Resistance Level | $39.60 | N/A |
| Average True Range (ATR) | 4.12 | 0.00 |
| MACD | 1.05 | 0.00 |
| Stochastic Oscillator | 66.75 | 0.00 |
Price Performance
Historical ComparisonAbout SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.